Pfizer Inc. (PFE) on Wednesday reported positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO in adults with relapsed or refractory multiple myeloma who had received at least one prior line of treatment.
The study met its primary endpoint, showing a statistically significant improvement in progression-free survival compared with standard-of-care daratumumab plus pomalidomide and dexamethasone.
The safety and tolerability profile of ELREXFIO was consistent with prior studies, with most treated patients remaining progression-free at the interim analysis. The trial is ongoing to assess overall survival, which was not yet mature at the time of analysis.
ELREXFIO is already approved in more than 35 countries, including the United States and the European Union for certain patients with relapsed or refractory multiple myeloma.
On Tuesday, Pfizer shares closed at $26.48, down 1.16%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.